Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Date:5/21/2012

NEW YORK, May 21, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) Congress, taking place May 24-27, 2012, in Paris, France.

The following poster will be presented on Saturday, May 26, 2012, from 9:30am to 10:45am local time:

  • A Meta-Analysis of Ferric Citrate for Hyperphosphatemia: The Effects of an Oral Iron-Containing Phosphate Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients (Abstract # SAP534)

Zerenex, the Company's oral, ferric iron-based drug candidate for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, is currently in Phase 3 clinical development pursuant to a Special Protocol Assessment (SPA) agreement with the FDA.  The Zerenex Phase 3 registration program is comprised of an already completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.

The above referenced abstract is available for viewing on-line at http://www.m-events.com/customer/2012/era-edta/data/12575.pdf.

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
(Date:7/31/2014)... , July 31, 2014 For its innovative ... California , Art,s-Way Scientific has earned a Modular ... With competition in over 30 categories, MBI,s contest is ... members, which include building manufacturers, dealers, and product and ... excellent example the capability of our team," said ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... 29 Pfizer Inc. (NYSE: PFE ) invites investors and the general ... at 10 a.m. EDT on Tuesday, August 3, 2010 . The purpose ... company,s Second Quarter 2010 Performance Report, to be issued that morning. , ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SUNNYVALE, Calif. , June 29 Accuray Incorporated ... announced today the appointment of Peter Fine as a member of ... replace board member Li Yu who has resigned effective June ... Fine currently serves ...
Cached Medicine Technology:Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts 2Accuray Appoints Peter Fine to Board of Directors 2Accuray Appoints Peter Fine to Board of Directors 3Accuray Appoints Peter Fine to Board of Directors 4
(Date:8/1/2014)... Seattle, Wa (PRWEB) August 01, 2014 ... Sores Fast book review recently updated by Vkool.com, ... remedies for relieving symptoms of cold sores ... in the neck ,     A sore throat ... ,     Eating, drinking, and sleeping are uncomfortable ...
(Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
(Date:8/1/2014)... 01, 2014 Fitness is something most people ... From walking around the block to biking ten or more ... easy to maintain throughout the year. The Forbes Living ... series which will feature special guests, tips to get started ... shape. The series will air on most popular cable television ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... Stress management can be difficult in this day and ... diminish rest and leisure time, stress can mount up and ... a way to manage stress in order to be healthy ... good sense of work-life balance is the key to managing ... of SF Custom Chiropractic. “Stress, left unchecked, can not only ...
Breaking Medicine News(10 mins):Health News:Get Rid Of Cold Sores Fast Book Review Exposes Ellie Gadsby's Guide For Treating Fever Blisters – Vkool.com 2Health News:Get Rid Of Cold Sores Fast Book Review Exposes Ellie Gadsby's Guide For Treating Fever Blisters – Vkool.com 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:Forbes Living to Air Fitness Forward Series 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2
... Postgraduate Services® (PPS®), renowned for its ... of an on-demand, interactive case study, ... Options for Mid-Face Volumizing, now available ... Applications explores treatment options for the ...
... Data Manipulation , ... Denver, CO (PRWEB) July 8, ... based in Melbourne, FL, has just recorded its 30th year in ... and data manipulation in particular. IRI's flagship CoSort product is used ...
... Only the Best Medical Travel Agencies , ... Vernon Hills, Illinois (PRWEB) ... up in the U.S., more and more medical tourism agencies (MTAs) are ... should be aware that not all MTAs are created equally. According to ...
... trials to recruit large percentage of African American ... ... can double,a person,s weight loss according to a study from Kaiser Permanente,s ... weight loss maintenance trials ever conducted, will be published in,the August issue ...
... -- hailed since their inception in 2000 as ... resulting in members forgoing care and discontinuing drugs ... newly published studies. , Under employer-offered CDHPs, members ... dedicated health-care account before insurance coverage begins. Proponents ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... report results for its fourth quarter and,fiscal year 2008, ... after,the market closes., A conference call to review ... EDT) and will be hosted by Euan S. Thomson, ...
Cached Medicine News:Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 2Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 3Health News:IRI, The CoSort Company, Marks 30 Years 2Health News:IRI, The CoSort Company, Marks 30 Years 3Health News:An American Appeal to Overseas Hospitals 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 4Health News:Members of consumer-driven health plans choosing less care 2Health News:Accuray Incorporated to Report Fourth Quarter and Fiscal Year 2008 Financial Results 2
For the quantitative determination of high density lipoprotein (HDL) in human serum....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Medicine Products: